JP2017533248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533248A5 JP2017533248A5 JP2017525075A JP2017525075A JP2017533248A5 JP 2017533248 A5 JP2017533248 A5 JP 2017533248A5 JP 2017525075 A JP2017525075 A JP 2017525075A JP 2017525075 A JP2017525075 A JP 2017525075A JP 2017533248 A5 JP2017533248 A5 JP 2017533248A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- pyridin
- oxo
- enyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077703P | 2014-11-10 | 2014-11-10 | |
| US62/077,703 | 2014-11-10 | ||
| PCT/US2015/060003 WO2016077378A1 (en) | 2014-11-10 | 2015-11-10 | Substituted pyrrolopyrdines as inhibitors of bromodomain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533248A JP2017533248A (ja) | 2017-11-09 |
| JP2017533248A5 true JP2017533248A5 (enExample) | 2018-12-20 |
| JP6669744B2 JP6669744B2 (ja) | 2020-03-18 |
Family
ID=54608969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525075A Expired - Fee Related JP6669744B2 (ja) | 2014-11-10 | 2015-11-10 | ブロモドメインのインヒビターとしての置換ピロロピリジン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10183009B2 (enExample) |
| EP (1) | EP3218375B1 (enExample) |
| JP (1) | JP6669744B2 (enExample) |
| CN (3) | CN116003409A (enExample) |
| MA (1) | MA40943A (enExample) |
| WO (1) | WO2016077378A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9227985B2 (en) | 2013-03-15 | 2016-01-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| CA2909941A1 (en) | 2013-04-24 | 2014-10-30 | Salk Institute For Biological Studies | Vitamin d receptor/smad genomic circuit gates fibrotic response |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| MY180775A (en) | 2014-04-23 | 2020-12-09 | Incyte Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| EP3218376B1 (en) | 2014-11-10 | 2019-12-25 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| JP6709792B2 (ja) | 2015-01-29 | 2020-06-17 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| US11319318B2 (en) * | 2015-03-05 | 2022-05-03 | Boehringer Ingelheim International Gmbh | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 |
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| KR102643344B1 (ko) * | 2016-06-20 | 2024-03-07 | 인사이트 코포레이션 | Bet 저해제의 결정질 고체 형태 |
| CN110167939B (zh) * | 2017-01-11 | 2021-12-31 | 江苏豪森药业集团有限公司 | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| CN110198941B (zh) * | 2017-01-25 | 2021-09-28 | 江苏豪森药业集团有限公司 | 吡咯并吡啶类n-氧化衍生物及其制备方法和应用 |
| EP3609896A4 (en) * | 2017-04-14 | 2020-11-04 | AbbVie Inc. | BROMODOMAIN INHIBITORS |
| WO2019023149A1 (en) * | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| KR20200101434A (ko) * | 2017-12-20 | 2020-08-27 | 베타 파머수티컬 컴퍼니 리미티드 | 브로모도메인 단백질 억제제로서 작동하는 화합물 및 조성물 |
| CN109970733B (zh) * | 2017-12-28 | 2020-05-08 | 新发药业有限公司 | 一种维罗非尼及其类似物的简便制备方法 |
| US10442799B1 (en) | 2018-04-07 | 2019-10-15 | Fuqiang Ruan | Heterocyclic compounds and uses thereof |
| CN110577526B (zh) * | 2018-06-07 | 2023-10-27 | 上海翰森生物医药科技有限公司 | 溴域结构蛋白抑制剂的盐及其制备方法和应用 |
| WO2020007322A1 (zh) * | 2018-07-04 | 2020-01-09 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
| CN110776508B (zh) | 2018-07-27 | 2021-07-16 | 海创药业股份有限公司 | 一种brd4抑制剂及其制备方法和用途 |
| CN110818609A (zh) * | 2018-08-11 | 2020-02-21 | 中国药科大学 | 3-乙酰基吲哚类brpf1抑制剂的制备方法及其用途 |
| WO2020132004A1 (en) * | 2018-12-20 | 2020-06-25 | Saint Louis University | Bet inhibitors for modulating dux4 expression in fshd |
| CN113874016A (zh) | 2019-01-29 | 2021-12-31 | 福宏治疗公司 | 化合物及其用途 |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| WO2021022163A2 (en) | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| KR20220133259A (ko) | 2020-01-29 | 2022-10-04 | 포그혼 쎄라퓨틱스 인크. | 화합물 및 이의 용도 |
| US12528825B2 (en) | 2020-01-29 | 2026-01-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| IL295709A (en) | 2020-03-05 | 2022-10-01 | C4 Therapeutics Inc | Compounds for targeted degradation of brd9 |
| CN115667254A (zh) * | 2020-05-21 | 2023-01-31 | 贝达药业股份有限公司 | 作为溴结构域蛋白质抑制剂的化合物和组合物 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| JP2023536139A (ja) * | 2020-07-29 | 2023-08-23 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| WO2022115753A1 (en) * | 2020-11-30 | 2022-06-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Merged scaffold taf1 inhibitors |
| CN115232123A (zh) * | 2021-04-23 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| WO2023283263A1 (en) | 2021-07-06 | 2023-01-12 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| JP2025525347A (ja) | 2022-06-16 | 2025-08-05 | アンフィスタ セラピューティクス リミテッド | 標的タンパク質分解のための新規の二官能性分子 |
| CA3267147A1 (en) | 2022-09-13 | 2024-03-21 | Amphista Therapeutics Limited | COMPOUNDS FOR THE TARGETED DEGRADATION OF A PROTEIN |
| WO2024193527A1 (zh) * | 2023-03-20 | 2024-09-26 | 山东新时代药业有限公司 | 作为溴结构域抑制剂的吡咯并[2,3-c]吡啶类化合物 |
| WO2025117674A1 (en) * | 2023-11-28 | 2025-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compounds for targeted degradation of taf1 |
| GB202319256D0 (en) | 2023-12-15 | 2024-01-31 | Amphista Therapeutics Ltd | Novel compounds for targeted protein degradation |
| WO2025191109A1 (en) | 2024-03-13 | 2025-09-18 | Amphista Therapeutics Limited | Combinations comprising brd9 bifunctional compounds and their use in the treatment of cancer |
| US12624035B2 (en) | 2024-09-06 | 2026-05-12 | Amphista Therapeutics Limited | Compounds for targeted protein degradation |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| CA2066428C (en) | 1989-09-08 | 2000-11-28 | Bert Vogelstein | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DK0659439T3 (da) | 1993-12-24 | 2002-01-14 | Merck Patent Gmbh | Immunkonjugater |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| HU216142B (hu) | 1994-07-21 | 1999-04-28 | Akzo Nobel N.V. | Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| EP0836605B1 (en) | 1995-07-06 | 2002-02-06 | Novartis AG | Pyrrolopyrimidines and processes for the preparation thereof |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
| DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ES2201484T3 (es) | 1997-05-06 | 2004-03-16 | Wyeth Holdings Corporation | Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal. |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| NZ503991A (en) | 1997-11-06 | 2001-11-30 | American Cyanamid Co | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| ES2188254T3 (es) | 1998-11-19 | 2003-06-16 | Warner Lambert Co | N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas. |
| JP2007291059A (ja) * | 2005-11-21 | 2007-11-08 | Japan Tobacco Inc | ヘテロ環化合物およびその医薬用途 |
| EP1953147A1 (en) * | 2005-11-21 | 2008-08-06 | Japan Tobacco, Inc. | Heterocyclic compound and medicinal application thereof |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20140094456A1 (en) * | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014125408A2 (en) * | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors |
| EP2970285B1 (en) | 2013-03-11 | 2019-04-17 | AbbVie Inc. | Fused tetracyclic bromodomain inhibitors |
| CN105026403B (zh) * | 2013-03-12 | 2018-05-18 | 艾伯维公司 | 四环布罗莫结构域抑制剂 |
| CN104211639A (zh) | 2013-06-05 | 2014-12-17 | 中国科学院上海药物研究所 | 一类炔基杂环类化合物及其应用 |
| JP6386035B2 (ja) | 2013-06-12 | 2018-09-05 | ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド | 金属酵素阻害剤化合物 |
| PE20160540A1 (es) * | 2013-06-28 | 2016-06-11 | Abbvie Inc | Inhibidores de bromodominios |
| US9399640B2 (en) * | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| US20150148372A1 (en) | 2013-11-26 | 2015-05-28 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081280A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
| US10233195B2 (en) * | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
| MY180775A (en) * | 2014-04-23 | 2020-12-09 | Incyte Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| EP3218376B1 (en) * | 2014-11-10 | 2019-12-25 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| MA40940A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| WO2016086200A1 (en) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| HK1245677A1 (zh) * | 2015-01-23 | 2018-08-31 | Aclaris Therapeutics, Inc. | 用於治疗炎症和癌症的杂环itk抑制剂 |
| JP6709792B2 (ja) | 2015-01-29 | 2020-06-17 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| JP6512051B2 (ja) * | 2015-09-28 | 2019-05-15 | 株式会社Ｊｖｃケンウッド | 端末装置、通信システム、通信方法、プログラム |
-
2015
- 2015-11-09 MA MA040943A patent/MA40943A/fr unknown
- 2015-11-10 CN CN202310032629.3A patent/CN116003409A/zh active Pending
- 2015-11-10 WO PCT/US2015/060003 patent/WO2016077378A1/en not_active Ceased
- 2015-11-10 JP JP2017525075A patent/JP6669744B2/ja not_active Expired - Fee Related
- 2015-11-10 CN CN201580072359.2A patent/CN107207493B/zh not_active Expired - Fee Related
- 2015-11-10 CN CN202211065963.0A patent/CN115583947A/zh active Pending
- 2015-11-10 EP EP15797766.1A patent/EP3218375B1/en active Active
-
2017
- 2017-05-10 US US15/592,013 patent/US10183009B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533249A5 (enExample) | ||
| JP2017533250A5 (enExample) | ||
| JP2017530176A5 (enExample) | ||
| Blake et al. | Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1 H-pyrazol-5-yl) amino) pyrimidin-4-yl) pyridin-2 (1 H)-one (GDC-0994), an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor in early clinical development | |
| AU2008236562B2 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | |
| CN101039673B (zh) | 用于治疗涉及细胞增殖的疾病的组合 | |
| TWI699355B (zh) | 喹唑啉化合物 | |
| Tan et al. | Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies | |
| TWI556820B (zh) | Ｈｓｐ９０抑制劑之組合 | |
| JP6669745B2 (ja) | ブロモドメインのインヒビターとしての置換ピロロピリジン | |
| TWI324159B (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| JP2017537100A5 (enExample) | ||
| JP6669744B2 (ja) | ブロモドメインのインヒビターとしての置換ピロロピリジン | |
| BRPI0813999A2 (pt) | ciclopentanos de pirimidil como inibidores de akt proteína cinase | |
| WO2022076917A1 (en) | Modulators of cell proliferation and uses thereof | |
| JP2017526696A5 (enExample) | ||
| JP2018501287A5 (enExample) | ||
| JP2019512535A5 (enExample) | ||
| JP2012515737A (ja) | メトトレキサートおよびｄｈｏｄｈ阻害剤を含む組合せ剤 | |
| JP2017525740A5 (enExample) | ||
| JP2017501983A5 (enExample) | ||
| JP2015514796A5 (enExample) | ||
| CN104470509A (zh) | 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 | |
| WO2022138944A1 (ja) | Ｓｗｉ／ｓｎｆ複合体機能異常がんの合成致死性に基づく治療法 | |
| CN105050602B (zh) | 作为pi3激酶抑制剂的吡啶化合物 |